Clinical trial
Combination Chemotherapy in Treating Patients With Recurrent or Refractory…
NCT00002588 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002588 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia |
| Official title | Phase I Trial of Sequential Topotecan(NSC 609699)and Etoposide for Patients With Relapsed, Refractory,or High Risk Acute Myeloid or Lymphoid Leukemia |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | etoposide, topotecan hydrochloride |
| Enrollment | 30 |
| Start date | Aug 1, 1994 |
| Primary completion | Jul 1, 2000 |
| Completion | Jan 1, 2001 |
| First posted | Jul 29, 2004 |
| Last update posted | Jun 11, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: